Novus portfolio company TC BioPharm signs US collaboration deal.

Scottish life sciences group TC BioPharm (TCB) secures a $16 million (£12 million) strategic collaboration with US bio-tech group Bluebird to discover and develop new cancer treatments. 

The tie-up will utilise TCB's leading gamma delta T Cell capabilities with Bluebird's expertise in CAR T and gene therapy product development to discover the next generation of blood and solid tumour product candidates.

The agreement with bluebird bio is a strategic collaboration and license agreement focused on development treatments centred around gamma-delta CAR T cells.

http://www.tcbiopharm.com/

Author: Clive Gunther